For the first time, the relationship of immunological parameters with the coefficient of quantitative anisotropy in the area of the corpus callosum in schizophrenia was revealed. The results indicate the possible value of indicators of the activation of the humoral immune response and systemic inflammation as markers of neurophysiological changes and cognitive dysfunction in schizophrenia. Levels of markers of systemic inflammation and growth factor VEGF-A as well as the activation of humoral immunity are increased in patients with schizophrenia compared with controls. For the first time, the relationship of immunological parameters with the coefficient of quantitative anisotropy in the area of the corpus callosum in schizophrenia was revealed. The results indicate the possible value of indicators of the activation of the humoral immune response and systemic inflammation as markers of neurophysiological changes and cognitive dysfunction in schizophrenia. In order to develop methods and means of maintaining normal human functioning under conditions of desynchronizes, the effect of mexidol on the level of corticosterone in the blood serum and the state of the cells of the beam zone of the adrenal cortex of rats after light or dark deprivation and physical activity to a state of fatigue. The experiments were performed on 7 groups of rats (10 animals each) in the spring. The model of physical activity is the method of forced swimming of rats until exhaustion in its own modification. For the induction of experimental desynchronizes, the animals of the experimental groups were kept around the clock for 10 days with artificial bright light of 150 LX or a complete darkening of 2-3 LX. Mexidol was administered intramuscularly at a dose of 10 mg/kg animal 30 minutes before the swimming test. Control animals under similar conditions were administered 0.9% sodium chloride solution. The level of corticosterone in the serum was determined using enzyme immunoassay. The tion in animals and the breakdown of adaptation. To study of efficacy and safety of mexidol used as intravenous infusion for 14 days, followed by per os treatment with mexidol FORTE 250 for 60 days in patients with chronic brain ischemia (CHM) complicated with arterial hypertension and atherosclerosis. The mexidol group included 27 patients (24 women and 3 men) with CHM I-II gr and the combination of arterial hypertension and atherosclerosis who received intravenous infusions of mexidol (500 mg once daily) within 14 days, with the subsequent per os treatment with mexidol FORTE 250 in a daily dose of 750 mg (1 tablet 3 times a day) for 60 days. The comparison group consisted of 30 patients (22 women and 8 men) with CHM I-II gr, comparable in age, nature of risk factors and expression of neurological manifestations. Patients in both groups received basic medications to treat their risk factors. Motor activity (Tinetti test), cognitive functions (MoCa test), anxiety and depression (Hamilton anxiety and depression scale), clinical condition (General Clinicaapy (day 74), patients in the mexidol group have a reliable improvement in motor activity, cognitive function and psychoemotional sphere, as well as a decrease in fatigue and neurological manifestations compared with the comparison group. To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the cognitive functions. The study included 51 patients with epilepsy aged 7 to 15 years. The children were divided into four groups depending on the prescribed treatment. https://www.selleckchem.com/products/SB590885.html The first study group ( =16) received intravenous reamberin once daily for 5 days in addition to carbamazepine. The second group ( =15) received intravenous reamberin once daily for 5 days in addition to valproic acid. Two comparison groups (10 patients each) received only carbamazepine or only valproic acid, respectively. Cognitive functions were assessed at admission and on the 6 day of treatment using Schulte tables (10 words). Reamberin significantly increases the work efficiency by 19-21%, and workability degree by 8-12% compared with the patients of the control groups. An analysis of the effect of succinate-containing drug on auditory memory has shown that the volumes of short-term memory and long-term memory are by 1.8 times and 1.3 times, respectively, higher than those in the control groups. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered clinically reasonable, and promising. Reamberin significantly increases the work efficiency by 19-21%, and workability degree by 8-12% compared with the patients of the control groups. An analysis of the effect of succinate-containing drug on auditory memory has shown that the volumes of short-term memory and long-term memory are by 1.8 times and 1.3 times, respectively, higher than those in the control groups. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered clinically reasonable, and promising. To analyze the efficacy and safety of fampridine** (Valenta Pharm, Russia) in the complex therapy of multiple sclerosis (MS). One hundred and twenty-six patients with MS were double blind randomized to receive fampridine ( =60) or placebo ( =66). Fampridine was administered in prolonged-release form (film-coated tablets, 10 mg) at a dose of 10 mg (1 tablet) 2 times a day, for 24 weeks. The placebo group was treated in the same way. From the 12th week, all patients in the placebo group were transferred to therapy with fampridine, 10 mg 2 times a day, for another 12 weeks. Concomitant standard therapy for MS was allowed in both groups (concomitant disease-modifying medications and other treatment). The primary outcome in the study was the proportion of patients with reduced t25fw test time (determining walking speed on a 25-foot path) on at least two out of three visits compared to baseline. The mean change in Multiple Sclerosis Functional Composite (MSFC) scores from baseline was assessed at visits 4-7 (8-24 weeks). The proportion of patients with reduced t25fw test time compared to the baseline level was 31.7% in the fampridine group, which is higher than in the placebo group - 3.0% ( <0.001). The overall result of the Multiple Sclerosis Functional Composite (MSFC) reflected a gradual improvement in the patient's condition during treatment period. The dynamics of MSFC result relative to the baseline level significantly differed ( <0.05) between the fampridine and placebo groups in favor of the fampridine group during all treatment periods. In the fampridine group, adverse events (AE) associated with disorders of the nervous system were more common headache, dizziness, and coordination disorders. Fampridine improves walking performance in MS patients. The Russian product fampridine has demonstrated a favorable safety profile. Fampridine improves walking performance in MS patients. The Russian product fampridine has demonstrated a favorable safety profile.